Table 2.
Multivariable analyses for disease-free survival and overall survival performed in younger (aged <60 years) patients with cytogenetically normal acute myeloid leukemia
| Variables | Disease-free survival (n=266) | Overall survival (n=315) | ||||
|---|---|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | HR (95% CI) | |||
| Age, continuous | 0.005 | 1.20 (1.06–1.37) | ||||
| DNMT3A, mut vs wt | <0.001 | 1.94 (1.41–2.67) | 0.003 | 1.58 (1.17–2.14) | ||
| FLT3-ITD, yes vs no | <0.001 | 2.31 (1.67–3.19) | <0.001 | 2.08 (1.55–2.80) | ||
| FLT3-TKD, mut vs wt | 0.04 | 0.52 (0.28–0.97) | ||||
| HG, continuous | 0.02 | 0.91 (0.84–0.98) | ||||
| RUNX1, mut vs wt | 0.002 | 2.82 (1.44–5.52) | <0.001 | 3.82 (2.17–6.75) | ||
| UPD of 11p, yes vs no | 0.04 | 0.35 (0.13–0.98) | ||||
| UPD of 13q, yes vs no | 0.009 | 2.10 (1.20–3.67) | ||||
| WT1, mut vs wt | 0.03 | 1.70 (1.04–2.77) | <0.001 | 2.62 (1.70–4.03) | ||
Abbreviations: UPD, uniparental disomy; CI, confidence interval; HG, hemoglobin levels; HR, hazard ratio; FLT3-ITD, internal tandem duplication of the FLT3 gene; mut, mutated; n, number; FLT3-TKD, tyrosine kinase domain mutation in the FLT3 gene; wt, wild-type
A HR >1 (< 1) corresponds to a higher (lower) risk for first category listed of a dichotomous variable or higher values of a continuous variable. A limited backward selection technique was used to build the final models with variables that were significant at the likelihood ratio test P-value <0.20 from univariable models for each outcome. For DFS those variables were: HG, platelet count, white blood cell count, UPD of 11p, UPD of 13q, FLT3-ITD status, biallelic mutation of CEBPA status, and mutation status of BCOR, DNMT3A, FLT3-TKD, GATA2, RUNX1, SMC1A, and WT1. For OS those variables were: age, HG, white blood cell count, UPD of 11p, UPD of 13q, FLT3-ITD status, biallelic mutation of CEBPA status, and mutation status of DNMT3A, FLT3-TKD, GATA2, RUNX1, SMC1A, WT1 and ZRSR2.